Blair William & Co. IL lessened its stake in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 13.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 582,159 shares of the biopharmaceutical company’s stock after selling 93,451 shares during the period. Blair William & Co. IL’s holdings in Bristol-Myers Squibb were worth $24,177,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in BMY. ESL Trust Services LLC purchased a new stake in shares of Bristol-Myers Squibb in the 1st quarter valued at $27,000. LGT Financial Advisors LLC boosted its position in Bristol-Myers Squibb by 42.7% during the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 227 shares during the period. MFA Wealth Advisors LLC bought a new position in Bristol-Myers Squibb in the 2nd quarter worth $39,000. Fairman Group LLC bought a new position in Bristol-Myers Squibb in the 4th quarter worth $42,000. Finally, Beach Investment Counsel Inc. PA bought a new position in Bristol-Myers Squibb in the 2nd quarter worth $42,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.
Bristol-Myers Squibb Stock Performance
Shares of BMY stock opened at $49.74 on Thursday. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $59.46. The company’s 50-day moving average is $47.34 and its 200 day moving average is $46.48. The company has a market capitalization of $100.83 billion, a price-to-earnings ratio of -16.05, a price-to-earnings-growth ratio of 12.59 and a beta of 0.46. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02 and a current ratio of 1.16.
Bristol-Myers Squibb Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.83%. The ex-dividend date of this dividend is Friday, October 4th. Bristol-Myers Squibb’s payout ratio is presently -77.42%.
Wall Street Analysts Forecast Growth
BMY has been the subject of several research reports. TD Cowen upped their price objective on shares of Bristol-Myers Squibb from $45.00 to $53.00 and gave the stock a “hold” rating in a report on Monday, August 12th. Cantor Fitzgerald restated a “neutral” rating and issued a $50.00 price objective on shares of Bristol-Myers Squibb in a report on Monday. Jefferies Financial Group upped their price objective on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a report on Wednesday, August 28th. Barclays upped their price objective on shares of Bristol-Myers Squibb from $41.00 to $42.00 and gave the stock an “underweight” rating in a report on Thursday, August 22nd. Finally, StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $55.00.
Read Our Latest Stock Report on Bristol-Myers Squibb
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Further Reading
- Five stocks we like better than Bristol-Myers Squibb
- Investing in Construction Stocks
- How Much Can You Make in Stocks in One Month?
- Health Care Stocks Explained: Why You Might Want to Invest
- This Is the Top Large-Cap Stock Insiders Are Buying
- What to Know About Investing in Penny Stocks
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.